Category GLP-1

GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro/Zepbound) have taken the world by storm. They help people lose significant amounts of weight by reducing appetite and quieting the constant “food noise” that so many struggle with.

But there’s a difficult truth emerging from the science: when people stop these drugs, they regain much of the weight they lost.

In fact, clinical trials show that within one year of stopping semaglutide, participants regained about two-thirds of the weight they had lost. Real-world data is even starker: by two years, 85% of patients have discontinued GLP-1 medications. By three years, fewer than 10% remain on them. And once the injections stop, hunger and cravings almost always return.

Obesity keeps rising, and we now seem to need drugs to combat it. But why?
In recent years, medications like Ozempic and other GLP-1 agonists have surged in popularity—not just as diabetes treatments, but as tools for weight loss. Their rise reflects something deeper than a personal health choice: a public surrender to a food environment that has become too powerful to resist. We don’t suddenly have less willpower—we have a radically different world. This article explores how changes in food supply, culture, industry influence, and lifestyle patterns have collided to create an obesity epidemic that now seems to require pharmaceutical intervention just to keep up. When you step back and compare nations with vastly different obesity rates—like the U.S., Japan, France, and South Korea—the patterns become undeniable. The data tells a story of how we got here—and why drugs may feel like the only answer in a system designed to keep us overeating.